WoldeMussie E - Search Results

1

Exploring the potential for subtype-selective muscarinic agonists in glaucoma.

Gil D, Spalding T, Kharlamb A, Skjaerbaek N, Uldam A, Trotter C, Li D, WoldeMussie E, Wheeler L, Brann M. Gil D, et al. Among authors: woldemussie e. Life Sci. 2001 Apr 27;68(22-23):2601-4. doi: 10.1016/s0024-3205(01)01058-x. Life Sci. 2001. PMID: 11392632

2

Role of alpha-2 adrenergic receptors in neuroprotection and glaucoma.

Wheeler LA, Gil DW, WoldeMussie E. Wheeler LA, et al. Among authors: woldemussie e. Surv Ophthalmol. 2001 May;45 Suppl 3:S290-4; discussion S295-6. doi: 10.1016/s0039-6257(01)00206-5. Surv Ophthalmol. 2001. PMID: 11377451

3

Alpha-2 adrenergic receptor agonists are neuroprotective in experimental models of glaucoma.

Wheeler LA, Woldemussie E. Wheeler LA, et al. Among authors: woldemussie e. Eur J Ophthalmol. 2001 Jul-Sep;11 Suppl 2:S30-5. doi: 10.1177/112067210101102s03. Eur J Ophthalmol. 2001. PMID: 11592528

4

Role of alpha-2 agonists in neuroprotection.

Wheeler L, WoldeMussie E, Lai R. Wheeler L, et al. Among authors: woldemussie e. Surv Ophthalmol. 2003 Apr;48 Suppl 1:S47-51. doi: 10.1016/s0039-6257(03)00004-3. Surv Ophthalmol. 2003. PMID: 12852434 Review.

5

Muscarinic receptor subtypes in human iris-ciliary body measured by immunoprecipitation.

Gil DW, Krauss HA, Bogardus AM, WoldeMussie E. Gil DW, et al. Among authors: woldemussie e. Invest Ophthalmol Vis Sci. 1997 Jun;38(7):1434-42. Invest Ophthalmol Vis Sci. 1997. PMID: 9191607

6

Neuroprotection of retinal ganglion cells by brimonidine in rats with laser-induced chronic ocular hypertension.

WoldeMussie E, Ruiz G, Wijono M, Wheeler LA. WoldeMussie E, et al. Invest Ophthalmol Vis Sci. 2001 Nov;42(12):2849-55. Invest Ophthalmol Vis Sci. 2001. PMID: 11687528

7

Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, I: Functional measures.

Hare WA, WoldeMussie E, Lai RK, Ton H, Ruiz G, Chun T, Wheeler L. Hare WA, et al. Among authors: woldemussie e. Invest Ophthalmol Vis Sci. 2004 Aug;45(8):2625-39. doi: 10.1167/iovs.03-0566. Invest Ophthalmol Vis Sci. 2004. PMID: 15277486

8

Efficacy and safety of memantine treatment for reduction of changes associated with experimental glaucoma in monkey, II: Structural measures.

Hare WA, WoldeMussie E, Weinreb RN, Ton H, Ruiz G, Wijono M, Feldmann B, Zangwill L, Wheeler L. Hare WA, et al. Among authors: woldemussie e. Invest Ophthalmol Vis Sci. 2004 Aug;45(8):2640-51. doi: 10.1167/iovs.03-0567. Invest Ophthalmol Vis Sci. 2004. PMID: 15277487

9

From the lab to the clinic: activation of an alpha-2 agonist pathway is neuroprotective in models of retinal and optic nerve injury.

Wheeler LA, Lai R, Woldemussie E. Wheeler LA, et al. Among authors: woldemussie e. Eur J Ophthalmol. 1999 Jan-Mar;9 Suppl 1:S17-21. doi: 10.1177/112067219900901S09. Eur J Ophthalmol. 1999. PMID: 10230601

10

Efficacy and safety of memantine, an NMDA-type open-channel blocker, for reduction of retinal injury associated with experimental glaucoma in rat and monkey.

Hare W, WoldeMussie E, Lai R, Ton H, Ruiz G, Feldmann B, Wijono M, Chun T, Wheeler L. Hare W, et al. Among authors: woldemussie e. Surv Ophthalmol. 2001 May;45 Suppl 3:S284-9; discussion S295-6. doi: 10.1016/s0039-6257(01)00200-4. Surv Ophthalmol. 2001. PMID: 11377450

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

38 results

Search Page

Filters